Reaching patients has never been easier. A study can be advertised across search, social platforms, registries and EHR-linked databases, and referrals arrive in volume. Enrollment rarely scales at the same rate. The gap is less a marketing problem than a definitional one: identifying someone who may be interested in a trial differs from establishing that they meet every clinical, laboratory and temporal requirement in the protocol.
A clinical trial recruitment platform can usually establish who carries a relevant diagnosis, who falls within the age range, and who lives within reach of an active site. Those are real capabilities, but they represent the opening stage of eligibility assessment rather than its conclusion because of the information that is incomplete, unstructured, out of date, or unavailable at first contact. The more useful question is not how many patients were identified, but how many reached the site with evidence enough to support a reliable eligibility decision.
Discovery is not Determination
Digital systems are good at spotting relevance: someone searching a condition, sitting in a registry, or carrying a diagnosis code.
But, relevance is not eligibility.
One patient may have the right diagnosis and the wrong disease stage; another may meet the age criterion but have received a prohibited therapy; a third may look appropriate on a code while lacking the pathology confirmation the protocol requires. In each case, the platform compares a simplified profile against a simplified reading of the protocol, while the coordinator must reconcile the full record with the full document.
Eligibility Criteria resist Simple Forms
"Patient must have breast cancer" fits in a dropdown. “Histologically confirmed HER2-negative metastatic breast cancer, measurable disease, adequate organ function and no prior exposure to a specified therapy class does not; that needs pathology, oncology notes, imaging, medication history and labs.
Criteria of this kind stack conditions, carve out exceptions, set washout periods and thresholds, and often defer to investigator judgment. Much of the detail sits in clinical narrative rather than structured fields, which is why coded data alone tends to be insufficient. Self-reported answers have limits too: "I finished chemo six weeks ago" is useful context, but a protocol may require the agent, the dose and the washout interval. Compressed into ten screening questions, the result is often high sensitivity with limited precision.
Missing Data isn't a Clean Record
Even with EHR access, evidence is scattered across notes, pathology, radiology, pharmacy systems, outside providers and scanned documents.
A particular risk is interpreting absence as compliance. No recorded prohibited medication may mean the patient never received one or that it was prescribed by another organization, documented only in narrative, or coded differently. Systems that reduce every criterion to eligible or ineligible obscure that difference; more useful designs separate satisfied, not satisfied, unavailable, conflicting, and needs manual review.
Diagnosis codes warrant similar caution. Generated primarily for reimbursement, they often carry little about subtype, molecular status, severity, or treatment response. A clinical trial recruiting platform built largely on coded data can narrow the search population effectively while still leaving most of the assessment burden with coordinators.
Time is easy to underestimate
No major surgery within 28 days. A stable medication dose for at least 12 weeks. Laboratory results within seven days of randomization.
Criteria like these require knowing not only whether an event occurred, but when, and whether the relevant window has passed. A point-in-time match therefore ages quickly: a patient ineligible today because of a washout period may qualify in two weeks, while one who appears suitable may begin a new therapy before the site makes contact.
Optimizing the Wrong End of the Funnel
Cost per lead, click-through and questionnaire completions are all measurable, but none are predictive of enrollment. A cheap lead that fails source verification costs more than an expensive one that randomizes. Automation belongs on the review queue, not the decision. One automated screening system cut the patients needing review by roughly 85% at 12.6% precision, valuable because it preserved sensitivity while shrinking workload, not because it confirmed anything. Results travel badly, too: accuracy at one institution tells you little about yours.
Good matches also die in the wrong workflow, as duplicates, or as alerts arriving after the treatment decision. And clinical fit doesn't settle for travel, caregiving, or language, nor the tendency of platforms trained on historical records to keep surfacing patients who resemble those already enrolled.
What an Effective Clinical Trial Recruitment Platform should do
Separate identification from confirmation, with a visible status per patient: potentially relevant, records requested, site review required, temporarily ineligible, unable to determine.
Show criterion-level evidence, the data, its source, its date and what's missing, because a score without it makes coordinators redo the assessment.
Combine coded data with language processing of notes, model time explicitly, re-evaluate as records change, land referrals in the system coordinators already use, and validate prospectively.
What counts as a "match," interested, potentially eligible, or clinically verified?
Which criteria are automated, and how is missing data handled?
Do you read unstructured notes, and can I see criterion-level evidence?
Was it validated prospectively, and is success measured in enrolments or leads?
Vague answers usually mean you're buying patient marketing.
What exactly matters in the whole process?
Eligibility is ultimately a clinical determination, drawing on protocol logic, longitudinal records, source verification, site capacity and professional judgment. Digital recruitment still earns its place within that, widening reach and surfacing candidates who would otherwise be missed.
For anyone evaluating a clinical trial patient recruitment platform, the question isn't how many patients it can find. It's how reliably it moves one from discovery to site-confirmed eligibility.
Frequently Asked Questions
A clinical trial recruitment platform is a digital system that identifies, engages, prescreens, or refers potential study participants using advertising, patient registries, EHR or claims data, questionnaires and algorithmic matching. Platforms differ in whether they stop at expressed interest or attempt criterion-level matching.
Recruitment locates and engages people who may be interested in a study. Prescreening tests those people against selected eligibility criteria before formal site screening. A referral that has passed recruitment alone establishes interest, not clinical fit.
Because the data available at first contact rarely resolves the protocol. Disease stage, molecular status, laboratory thresholds and washout periods usually sit in pathology reports, clinical narrative and pharmacy records that the platform never sees.
Coded values automate fairly reliably, including age ranges, diagnosis codes, laboratory results and prescription histories. Histological confirmation, disease stage, performance status and investigator-assessed factors resist automation, which makes partial automation with flagged review the realistic target.
Reported performance varies widely. One automated screening study cut review volume by roughly 85% at 12.6% precision, while common-data-model systems report higher prospective accuracy in defined oncology settings. High sensitivity with modest precision supports triage rather than determination.
Usually yes, because source data replaces self-reported history. The gain depends on which parts of the record are reachable, along with terminology mapping, data completeness and whether care delivered elsewhere is visible at all.
On downstream outcomes rather than lead volume: referrals with retrievable records, prescreening pass rate, screen-failure rate, enrollment yield and coordinator time per enrolled participant. Positive predictive value matters more than cost per lead.
Blog
Why 60% of AI Projects Stall in Biopharma
Why AI value in Life Sciences now depends on data pipelines, not better models
Industry forecasts warn 60% of AI projects will fail. In Life Sciences, reliable AI depends on engineering discipline: real-time data pipelines, built-in governance, unstructured data readiness, and workflow-native execution.
Why care still slows down when data is digital, and how orchestration fixes it
Digital records alone do not fix care delays. See how healthcare interoperability, workflow-native platforms, and orchestration build the invisible infrastructure that turns data into coordinated action across health systems.
The real bottleneck in healthcare AI isn’t intelligence. It’s execution.
Why most healthcare AI stops at insight, and how leaders turn that into action
Healthcare AI has moved past experimentation, yet most initiatives stall between insight and action. See why execution, workflow integration, and product engineering decide which organizations turn intelligence into outcomes.
